{"id":762838,"date":"2023-06-09T18:28:30","date_gmt":"2023-06-09T22:28:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/"},"modified":"2023-06-09T18:28:30","modified_gmt":"2023-06-09T22:28:30","slug":"allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/","title":{"rendered":"Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501\/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>Long-Term Follow Up Data from Phase 1 ALPHA\/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies<\/li>\n<li>Presentation Recaps 12 Patients Treated with Phase 2 Dose Regimen and Includes Additional Data on All 33 CAR T Na\u00efve Patients Treated with the Alloy\u2122 Manufacturing Process<\/li>\n<li>Potentially Pivotal Phase 2 ALPHA2 Trials Ongoing in the US; Sites in Europe, Canada and Australia Expected to Enroll During 2023<\/li>\n<\/ul>\n<p>SOUTH SAN FRANCISCO, Calif., June  09, 2023  (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) products for cancer,\u00a0today announced it will present data from the Phase 1 ALPHA\/ALPHA2 trials of ALLO-501\/501A in patients with relapsed\/refractory (r\/r) large B-cell lymphoma (LBCL) in an oral presentation at the International Conference on Malignant Lymphoma (ICML) on June\u00a013\u201317, 2023 in\u00a0Lugano, Switzerland. This presentation will feature additional data on the 33 CAR T na\u00efve patients treated with the Alloy\u2122 manufacturing process across different CAR T dosing and lymphodepletion regimens. Earlier in June, data from the 12 patients who received a single ALLO-501\/A cell infusion following the lymphodepletion regimen being utilized in the ongoing potentially pivotal Phase 2 trials was presented at American Society of Clinical Oncology (ASCO) Annual Meeting.<\/p>\n<p>The ALPHA\/ALPHA2 Phase 1 trials were designed to assess the safety, tolerability, and preliminary efficacy at increasing dose levels of ALLO-501 and ALLO-501A, allogeneic CAR T cell product candidates that target CD19. In addition to exploring multiple cell doses and dosing schedules (consolidation), these studies evaluated various doses of ALLO-647, Allogene\u2019s proprietary lymphodepleting antibody designed to prevent premature rejection of AlloCAR T cells. Allogene is currently enrolling the potentially pivotal Phase 2 ALPHA2 trial of ALLO-501A in LBCL and expects to complete enrollment in 1H2024. The Company expects to open trial sites in Europe, Canada and Australia during 2023.<\/p>\n<p>\n        <u>Allogene Presentation at the 2023 ICML Lugano:<\/u>\n      <\/p>\n<p>\n        <strong>Durable responses with anti-CD19 allogeneic CAR T ALLO-501\/501A in phase 1 trials of relapsed\/refractory large B-cell lymphoma (r\/r LBCL)<\/strong>\n      <\/p>\n<p>Presenter: Dr.\u00a0Frederick Locke, M.D., Chair,\u00a0Department of Blood and Marrow Transplant\u00a0and Cellular Immunotherapy; program co-leader, Immuno-Oncology,\u00a0Moffitt Cancer Center Tampa, Florida<br \/>Abstract:\u00a0#48<br \/>Oral Presentation Date and Time: June 15, 2023, 15:30 CEST \/ 9:30am EST \/ 6:30am PST<\/p>\n<p>\n        <strong>About ALLO-501 and ALLO-501A<\/strong><br \/>\n        <br \/>ALLO-501 and ALLO-501A are anti-CD19 AlloCAR T\u2122 investigational products for the treatment of large B cell lymphoma. ALLO-501A, a next-generation anti-CD19 AlloCAR T\u2122, eliminates the rituximab recognition domains in ALLO-501, which could allow for use in a broader patient population, including NHL patients with recent rituximab exposure.\u00a0This product candidate is currently being studied in an ongoing Phase 2 trial. In June 2022, the\u00a0U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to ALLO-501A in r\/r LBCL.<\/p>\n<p>\n        <strong>About Allogene Therapeutics<\/strong><br \/>\n        <br \/>Allogene Therapeutics, with headquarters in\u00a0South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T\u2122) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of \u201coff-the-shelf\u201d CAR T product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-DYnaPAqKRSfRqzu5mtzrdAGSA1M5NjutTox-Qg8N5ySXpxI7_qKJSZ_UgNtk8VcXtXUoLhemxLfB4ZJ8qfHolrtfuDUfNWaCOqv6KCobKUWh6E7XCy265TAh3VLEPM_eL2VsSTJUqm3sXHaAworIFzxgAoMcXg-WB8ecLxuNN2l33S49mOWdz6Ym2BgxGsW_GltZ8yk75CTV4JgMLOKLF4_1BB-ESr8U_OXZ9VXkrY=\" rel=\"nofollow noopener\" target=\"_blank\">www.allogene.com<\/a>, and follow @AllogeneTx on Twitter and LinkedIn.<\/p>\n<p>\n        <strong>Cautionary Note on Forward-Looking Statements for Allogene<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as \u201ccould,\u201d \u201cdesigned,\u201d \u201cexpects,\u201d \u201cpotential,\u201d \u201cpreliminary,\u201d \u201cwill\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential of allogeneic CD19 CAR T product candidates to generate durable complete responses similar to approved autologous therapies; the potential of the Phase 2 ALPHA2 trial to be a pivotal trial; Allogene\u2019s expectation to complete enrollment of the Phase 2 ALPHA2 trial in the first half of 2024; Allogene\u2019s expectation to open trial sites for the Phase 2 ALPHA2 trial in Europe, Canada and Australia during 2023; the design of Allogene\u2019s trials and ALLO-647; data results that may be implied from prior results; and the potential benefits of AlloCAR T products. Various factors may cause material differences between Allogene\u2019s expectations and actual results, including, risks and uncertainties related to: our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval; Phase 1 data from our clinical trials is limited and may change as more patient data become available or may not be validated in any future or advanced clinical trial; our ability to maintain intellectual property rights necessary for the continued development of our product candidates, including pursuant to our license agreements; our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval or limit their commercial potential; the extent to which COVID-19 adversely impacts our business, including our clinical trials; the extent to which the\u00a0FDA\u00a0disagrees with our clinical or regulatory plans, which could cause future delays to our clinical trials or require additional clinical trials; we may encounter difficulties enrolling patients in our clinical trials; we may not be able to demonstrate the safety and efficacy of our product candidates in our clinical trials, which could prevent or delay regulatory approval and commercialization; challenges with manufacturing or optimizing manufacturing of our product candidates; and our ability to obtain additional financing to develop our products and implement our operating plans. These and other risks are discussed in greater detail in Allogene\u2019s filings with the\u00a0SEC, including without limitation under the \u201cRisk Factors\u201d heading of its Form 10-Q for the quarter ended\u00a0March 31, 2023. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p>Caution should be exercised regarding statements comparing autologous CAR T data. There are differences in the clinical trial design, patient populations, published data, follow-up times and the product candidates themselves, and the results from the clinical trials of autologous products may have no interpretative value on Allogene\u2019s existing or future results.<\/p>\n<p>AlloCAR T\u2122 and Alloy\u2122 are trademarks of\u00a0Allogene Therapeutics, Inc.<\/p>\n<p>Allogene\u2019s AlloCAR T\u2122 programs utilize the Cellectis TALEN<sup>\u00ae<\/sup>\u00a0technologies. ALLO-501 and ALLO-501A are anti-CD19 products being jointly developed under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S.<\/p>\n<p>\n        <strong>Allogene Media\/Investor Contact:<\/strong><br \/>\n        <br \/>Christine Cassiano<br \/>Chief Communications Officer<br \/>(714) 552-0326<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hwXMdRFELDDPbfeixfn4eroMMTiaZnFvm7YjbFGI6xuPZoM-D3Q3ZIipacgmoqHZgyNtVblGit_QsDLa_dwsv-EvjPLEvtm4-Ot_i8T5lvU1htGVa_vMEq9QjmqwUzva\" rel=\"nofollow noopener\" target=\"_blank\">Christine.Cassiano@allogene.com<\/a><\/p>\n<p>\n        <strong>Additional Allogene Media Contact:<\/strong><br \/>\n        <br \/>Madeleine Goldstein<br \/>Manager, Corporate &amp; Pipeline Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kauq3pLPu4-gcj_O_wt47sAgbI1NQfnM1It-zXViIvdFg6PZCFI0NqQ1Znl-QAWVFfZvRFzBryYBxqOHd1iP1vtevdi862gMfl-GJQwbmMh-C1Hze6qqKybuagi7sqxX\" rel=\"nofollow noopener\" target=\"_blank\">Madeleine.Goldstein@allogene.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTg5MiM1NjQwNDE0IzIxMjQyNDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/N2VhMzkyOGItZmQ4OC00ZGExLWFhMGMtZmJhMWE2ZjQ0YTI5LTExMzU4MTg=\/tiny\/Allogene-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Long-Term Follow Up Data from Phase 1 ALPHA\/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Recaps 12 Patients Treated with Phase 2 Dose Regimen and Includes Additional Data on All 33 CAR T Na\u00efve Patients Treated with the Alloy\u2122 Manufacturing Process Potentially Pivotal Phase 2 ALPHA2 Trials Ongoing in the US; Sites in Europe, Canada and Australia Expected to Enroll During 2023 SOUTH SAN FRANCISCO, Calif., June 09, 2023 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) products for cancer,\u00a0today announced it will present data from the Phase 1 ALPHA\/ALPHA2 trials of ALLO-501\/501A in patients &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501\/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-762838","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501\/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501\/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Long-Term Follow Up Data from Phase 1 ALPHA\/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Recaps 12 Patients Treated with Phase 2 Dose Regimen and Includes Additional Data on All 33 CAR T Na\u00efve Patients Treated with the Alloy\u2122 Manufacturing Process Potentially Pivotal Phase 2 ALPHA2 Trials Ongoing in the US; Sites in Europe, Canada and Australia Expected to Enroll During 2023 SOUTH SAN FRANCISCO, Calif., June 09, 2023 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) products for cancer,\u00a0today announced it will present data from the Phase 1 ALPHA\/ALPHA2 trials of ALLO-501\/501A in patients &hellip; Continue reading &quot;Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501\/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-09T22:28:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTg5MiM1NjQwNDE0IzIxMjQyNDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501\\\/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano\",\"datePublished\":\"2023-06-09T22:28:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\\\/\"},\"wordCount\":1188,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NTg5MiM1NjQwNDE0IzIxMjQyNDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\\\/\",\"name\":\"Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501\\\/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NTg5MiM1NjQwNDE0IzIxMjQyNDc=\",\"datePublished\":\"2023-06-09T22:28:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NTg5MiM1NjQwNDE0IzIxMjQyNDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NTg5MiM1NjQwNDE0IzIxMjQyNDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501\\\/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501\/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/","og_locale":"en_US","og_type":"article","og_title":"Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501\/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano - Market Newsdesk","og_description":"Long-Term Follow Up Data from Phase 1 ALPHA\/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation Recaps 12 Patients Treated with Phase 2 Dose Regimen and Includes Additional Data on All 33 CAR T Na\u00efve Patients Treated with the Alloy\u2122 Manufacturing Process Potentially Pivotal Phase 2 ALPHA2 Trials Ongoing in the US; Sites in Europe, Canada and Australia Expected to Enroll During 2023 SOUTH SAN FRANCISCO, Calif., June 09, 2023 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) products for cancer,\u00a0today announced it will present data from the Phase 1 ALPHA\/ALPHA2 trials of ALLO-501\/501A in patients &hellip; Continue reading \"Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501\/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-09T22:28:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTg5MiM1NjQwNDE0IzIxMjQyNDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501\/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano","datePublished":"2023-06-09T22:28:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/"},"wordCount":1188,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTg5MiM1NjQwNDE0IzIxMjQyNDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/","name":"Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501\/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTg5MiM1NjQwNDE0IzIxMjQyNDc=","datePublished":"2023-06-09T22:28:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTg5MiM1NjQwNDE0IzIxMjQyNDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTg5MiM1NjQwNDE0IzIxMjQyNDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-oral-presentation-of-phase-1-data-on-allo-501-501a-in-large-b-cell-lymphoma-at-the-international-conference-on-malignant-lymphoma-icml-lugano\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501\/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/762838","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=762838"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/762838\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=762838"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=762838"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=762838"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}